Paras Biopharmaceuticals Finland Oy, a startup company of University of Oulu, has developed technology for the production of an osteoporosis drug which will result into a very economical production of the medicine.
It has recently secured necessary investment from a UK based ASAP Growth Ltd who has extensive entrepreneurial experience in pharmaceuticals. This multi-million-euro investment is a key enabler in bringing further development of the product and the potential expansion of activities in Oulu.
The technologies of Paras Biopharmaceuticals are partly based on the research made at research group of Prof. Lloyd Ruddock at the Faculty of Biochemistry and Molecular Medicine.
Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments